

Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions

Recommendations from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has reviewed all available treatments for cancer to update the MOH List of Subsidised Drugs in line with local clinical practice and medical advancements. As part of this review, individual Technology Guidances¹ have been prepared which describe the subsidy recommendations for many cancer drugs for specific clinical conditions. The remaining treatments which have been considered by the Committee are included in this document.

Based on the available evidence, the Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Afatinib 20 mg, 30 mg and 40 mg tablets;
- ✓ Azacitidine 100 mg injection;
- ✓ Bendamustine 25 mg and 100 mg concentrate for infusion;
- ✓ Bicalutamide 50 mg tablet;
- ✓ Cisplatin 100 mg/100 mL concentrate for infusion;
- ✓ Cyproterone 50 mg tablet;
- ✓ Dabrafenib 50 mg and 75 mg capsules;
- ✓ Epirubicin 50 mg/25 mL injection;
- ✓ Eribulin mesylate 1 mg/2 mL solution for injection;
- ✓ Erlotinib 100 mg and 150 mg tablets (Inerlotinib);
- ✓ Exemestane 25 mg tablet;
- ✓ Fludarabine phosphate 50 mg injection;
- ✓ Fulvestrant 250 mg/5 mL solution for injection (Femcord);
- ✓ Gefitinib 250 mg tablet (Ingefitinib);
- ✓ Goserelin 3.6 mg and 10.8 mg depot injections;
- ✓ Imatinib 100 mg and 400 mg tablets (Veenat);
- ✓ Lapatinib 250 mg tablets;

¹ Technology guidances will be published on the ACE website between 4 January 2022 and 1 September 2022.

Updated: 1 April 2022

- ✓ Lenalidomide 5 mg, 10 mg, 15 mg and 25 mg capsules (Lenli);
- ✓ Leuprorelin acetate 3.75 mg depot injection;
- ✓ Megestrol 40 mg and 160 mg capsules;
- ✓ Oxaliplatin 200 mg/40 mL concentrate for infusion;
- ✓ Paclitaxel-albumin bound nanoparticles 100 mg injectable suspension;
- ✓ Pazopanib 200 mg and 400 mg tablets;
- ✓ Pegylated liposomal doxorubicin 20 mg concentrate for infusion (Chemodox);
- ✓ Pembrolizumab 100 mg/4 mL solution for infusion;
- ✓ Pemetrexed 100 mg and 500 mg injections;
- ✓ Trametinib 0.5 mg and 2 mg tablets; and
- ✓ Vinorelbine 50 mg/5 mL injection

for inclusion on the MOH Standard Drug List (SDL) or Medication Assistance Fund (MAF) in line with their registered indications or specific clinical criteria for treating cancer, in view of clinical need, and acceptable clinical and cost effectiveness.

Drugs that have not been recommended for subsidy are listed in the Annex.

For all drugs, the clinical indications, subsidy class, subsidy implementation dates (if applicable), and MediShield Life claim limits are provided in the Annex.

ANNEX

Recommendations by the MOH Drug Advisory Committee

Drug preparation (Brand)	Clinical indications	Subsidy class (implementation date)	MediShield Life claim limit per month (implementation date)
Acute myeloid leukaemia			
Idarubicin 5 mg/5 mL and 10 mg/10 mL solution for injection	Treatment of adults with acute myeloid leukaemia for remission induction.	Not recommended for subsidy	\$400 (1 Sep 2022)
Breast cancer			
Eribulin mesylate 1 mg/2 mL solution for injection	Treatment of locally advanced or metastatic breast cancer in patients whose disease has progressed after 2 or more chemotherapy regimens for advanced disease.	MAF (1 Sep 2022)	\$1200 (1 Sep 2022)
Everolimus 2.5 mg, 5 mg and 10 mg tablets	In combination with exemestane for HR-positive, HER2-negative advanced breast cancer, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.	Not recommended for subsidy	\$1200 (1 Sep 2022)
Fulvestrant 250 mg/5 mL solution for injection	For cancer treatment.	SDL subsidy only applies to generic brand Femcord used in the PHIs (1 Apr 2022)	TBD
Goserelin acetate 3.6 mg and 10.8 mg depot injections**	Treatment of breast cancer in pre- and perimenopausal women in whom hormone therapy is specified.	MAF (4 Jan 2022)	\$200 (1 Sep 2022)
Lapatinib 250 mg tablet	Lapatinib in combination with an aromatase inhibitor for postmenopausal women with HR-positive, HER2-positive metastatic breast cancer.	MAF (1 Sep 2022)	\$600 (1 Sep 2022)
	Lapatinib in combination with capecitabine for HER2-positive, advanced or metastatic breast cancer in patients whose disease has progressed after treatment with an anthracycline and, a taxane, and on prior trastuzumab in the metastatic setting.	MAF (1 Sep 2022)	\$600 (1 Sep 2022)
Leuprorelin acetate 3.75 mg depot injection **	Treatment of breast cancer in pre- and perimenopausal women in whom hormone therapy is specified.	MAF (4 Jan 2022)	\$200 (1 Sep 2022)
Paclitaxel-albumin bound nanoparticles 100 mg injectable suspension	Monotherapy for breast cancer in adults who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.	MAF (1 Sep 2022)	\$1000 (1 Sep 2022)
Vinorelbine 20 mg and 30	Treatment of advanced breast cancer.	Not recommended	TBD

mg capsules		for subsidy	
B-cell lymphoma			
Rituximab 1400 mg/11.7 mL solution for subcutaneous injection	Rituximab (subcutaneous) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), for the treatment of CD20+ diffuse large B-cell non-Hodgkin lymphoma.	Not recommended for subsidy	\$1000 (1 Sep 2022)
	Rituximab (subcutaneous) in combination with cyclophosphamide, vincristine, prednisone (CVP), for the treatment of previously untreated patients with stage III-IV follicular lymphoma.	Not recommended for subsidy	\$1000 (1 Sep 2022)
	Rituximab (subcutaneous) for maintenance treatment of patients with follicular lymphoma who have responded to induction therapy.	Not recommended for subsidy	\$1000 (1 Sep 2022)
Gastric cancer			
Tegafur/gimeracil/oteracil potassium 20 mg/5.8 mg/19.6 mg and 25 mg/7.25 mg/24.5 mg capsules	Post-operative adjuvant treatment of locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer.	Not recommended for subsidy	\$200 (1 Sep 2022)
Lung cancer			
Afatinib 20 mg, 30 mg and 40 mg tablets	Treatment of locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer.	MAF (1 Sep 2022)	\$600 (1 Sep 2022)
Dabrafenib 50 mg and 75 mg capsules, trametinib 0.5 mg and 2 mg tablets	Dabrafenib in combination with trametinib for the treatment of advanced non-small-cell lung cancer in patients with a BRAF V600 mutation.	MAF (4 Jan 2022)	\$3800 (1 Sep 2022)
Erlotinib 100 mg and 150 mg tablets	Treatment of locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer.	SDL subsidy only applies to generic brand Inerlotinib used in the PHIs (1 Feb 2022)	\$200 (1 Sep 2022)
Gefitinib 250 mg tablet	Treatment of locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer.	SDL subsidy only applies to generic brand Ingefitinib used in the PHIs (1 Feb 2022)	\$200 (1 Sep 2022)
Paclitaxel-albumin bound nanoparticles 100 mg injectable suspension	Nab-paclitaxel in combination with carboplatin, for previously untreated locally advanced or metastatic non-small-cell lung cancer in patients who are not candidates for curative surgery or radiation therapy.	MAF (1 Sep 2022)	\$1000 (1 Sep 2022)
Vinorelbine 20 mg and 30 mg capsules	Treatment of non-small-cell lung cancer.	Not recommended for subsidy	TBD
Merkel cell cancer			
Avelumab 200 mg/ 10 mL concentrate for solution	Treatment of metastatic Merkel cell carcinoma.	Not recommended for subsidy	\$1800 (1 Sep 2022)

for infusion			
Pembrolizumab 100 mg/4 mL solution for infusion	Treatment of metastatic Merkel cell carcinoma.	MAF (1 Sep 2022)	\$1800 (1 Sep 2022)
Multicentric Castleman's disease			
Siltuximab 100 mg powder for infusion	Treatment of adults with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.	Not recommended for subsidy	\$3000 (1 Sep 2022)
Multiple myeloma			
Lenalidomide 5 mg, 10 mg, 15 mg and 25 mg capsules	Treatment of multiple myeloma.	SDL subsidy only applies to generic brand Lenli used in the PHIs (4 Jan 2022)	\$1200 (1 Sep 2022)
Ovarian cancer			
Pegylated liposomal doxorubicin 20 mg concentrate for infusion	Treatment of advanced ovarian cancer in patients who have failed a first-line platinum-based chemotherapy regimen.	SDL subsidy only applies to generic brand Chemodox used in the PHIs (1 Feb 2022)	\$1400 (1 Sep 2022)
Pancreas Cancer			
Paclitaxel-albumin bound nanoparticles 100 mg injectable suspension	Nab-paclitaxel in combination with gemcitabine, for previously untreated metastatic adenocarcinoma of the pancreas.	MAF (1 Sep 2022)	\$1000 (1 Sep 2022)
Pegylated liposomal irinotecan concentrate for dispersion for infusion (43 mg/10 mL)	Liposomal irinotecan in combination with fluorouracil and leucovorin, for patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.	Not recommended for subsidy	\$200 (1 Sep 2022)
Tegafur/gimeracil/ oteracil potassium 20 mg/5.8 mg/19.6 mg and 25 mg/7.25 mg/24.5 mg capsules	Treatment of locally advanced or metastatic adenocarcinoma of the pancreas.	Not recommended for subsidy	\$200 (1 Sep 2022)
Prostate Cancer			
Bicalutamide 50 mg tablet	Treatment of prostate cancer.	SDL (4 Jan 2022)	\$200 (1 Sep 2022)
Cyproterone 50 mg tablet	Treatment of prostate cancer.	SDL (4 Jan 2022)	\$200 (1 Sep 2022)
Triptorelin 3.75 mg, 11.25 mg and 22.5 mg injections	Treatment of locally advanced or metastatic, hormone-dependent prostate cancer.	Not recommended for subsidy	\$200 (1 Sep 2022)
Radium-223 solution for injection (1100 kBq/mL)	Treatment of patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.	Not recommended for subsidy	\$1400 (1 Sep 2022)
Soft tissue sarcoma			
Eribulin mesylate 1 mg/2	Treatment of adults with unresectable	MAF	\$1200

mL solution for injection	liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.	(1 Sep 2022)	(1 Sep 2022)
Pazopanib 200 mg and 400 mg tablets	Treatment of adults with selective subtypes* of soft tissue sarcoma who have received prior chemotherapy for metastatic disease or whose disease has progressed within 12 months after (neo)adjuvant therapy. *as per subtypes listed in the product insert	SDL (4 Jan 2022)	\$1600 (1 Sep 2022)
Pegylated liposomal doxorubicin 20 mg concentrate for infusion	Treatment of soft tissue sarcoma.	SDL subsidy only applies to generic brand Chemodox used in the PHIs (1 Feb 2022)	\$1400 (1 Sep 2022)
Trabectedin 1 mg powder for injection	Treatment of advanced or metastatic soft tissue sarcoma, after failure of anthracyclines and ifosfamide (unless unsuitable).	Not recommended for subsidy	\$1200 (1 Sep 2022)
Waldenstrom's Macroglobulinaemia			
Ibrutinib 140 mg capsule, and 140 mg, 280 mg, 420 mg tablets	Ibrutinib as a single agent, or in combination with rituximab biosimilar, for the treatment of Waldenstrom's Macroglobulinaemia.	Not recommended for subsidy	\$2000 (1 Sep 2022)
Various types of cancer			
Azacitidine 100 mg injection	For cancer treatment.	SDL (4 Jan 2022)	\$400 (1 Sep 2022)
Bendamustine 25 mg and 100 mg concentrate for infusion	For cancer treatment.	SDL (4 Jan 2022)	\$800 (1 Sep 2022)
Cisplatin 100 mg/100 mL concentrate for infusion	For cancer treatment.	SDL (4 Jan 2022)	\$200 (1 Sep 2022)
Epirubicin 50 mg/25 mL injection	For cancer treatment.	SDL (4 Jan 2022)	\$600 (1 Sep 2022)
Exemestane 25 mg tablet	For cancer treatment.	SDL (4 Jan 2022)	\$200 (1 Sep 2022)
Fludarabine phosphate 50 mg injection	For cancer treatment.	SDL (4 Jan 2022)	\$600 (1 Sep 2022)
Imatinib 100 mg and 400 mg tablets	For cancer treatment.	SDL subsidy only applies to generic brand Veenat (1 Feb 2022) used in the PHIs	\$200 (1 Sep 2022)
Megestrol 40 mg and 160 mg capsules	For cancer treatment.	SDL (4 Jan 2022)	\$200 (1 Sep 2022)
Oxaliplatin 200 mg/40 mL concentrate for infusion	For cancer treatment.	SDL (4 Jan 2022)	\$200 (1 Sep 2022)
Pemetrexed 100 mg and	For cancer treatment.	SDL	\$200

500 mg injections		(4 Jan 2022)	(1 Sep 2022)
Vinorelbine 50 mg/5 mL injection	For cancer treatment.	SDL (4 Jan 2022)	\$400 (1 Sep 2022)

Abbreviations: PHI, public healthcare institution; SDL, Standard Drug List; MAF, Medication Assistance Fund; TBD, to be determined.

** MAF assistance does not apply to other formulations and/or strengths of goserelin or leuprorelin for the treatment of breast cancer.

VERSION HISTORY

Update of MOH List of subsidised drugs to include treatments for various cancer conditions

This Version History is provided to track any updates or changes to the guidance following the first publication date. It is not part of the guidance.

1. Publication of guidance

Date of Publication 4 Jan 2022

2. Guidance updated to include more drugs

Date of Publication 1 Apr 2022

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government subsidy decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

This guidance is based on the evidence available to the MOH Drug Advisory Committee as at 16 March 2021, 27 May 2021, 2 July 2021, 18 August 2021, 12 October 2021, 13 December 2021 and 18 February 2022. It is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Chief HTA Officer
 Agency for Care Effectiveness
 Email: ACE_HTA@moh.gov.sg

In citation, please credit the "Ministry of Health, Singapore" when you extract and use the information or data from the publication.